Received Sep 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | 1 | UT8792LA | OT |
vaccine flu trivalent administered during pregnancy with no reported adverse event; Initial information received on 27-Aug-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 34 years old female patient who was exposed to vaccine influenza USP trival A-B subvirion NO preservative vaccine [fluzone] in context of vaccine flu trivalent administered during pregnancy with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported vaccine flu trivalent administered during pregnancy with no reported adverse event occurred at 33 Weeks of pregnancy and the patient was exposed to influenza USP trival A-B subvirion NO preservative vaccine at 33 weeks of pregnancy, during third pregnancy trimester for influenza USP TRIVAL A-B subvirion NO preservative vaccine. The date of last menstrual period was reported as 11-Jan-2025. The estimated due date is 18-Oct-2025. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 27-Aug-2025, the patient received Dose 1 of suspect influenza USP trival A-B subvirion NO preservative vaccine Suspension for injection (Unknown strength) with UT8792LA and expiry date Jun-2026 via intramuscular route in unknown administration site for Prophylactic vaccination (Immuisation) during pregnancy with no reported adverse event (Exposure during pregnancy) (Latency same day) There were no information related to relevant prenatal testing after exposure. Action taken was not applicable. Additionally, at time of reporting, the pregnancy is still ongoing.